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TECHNICAL NOTE
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While the use of monoclonal antibodies has added a new
dimension to the detection and characterization of glomerular
immune deposits in human renal diseases, it carries at least one
serious limitation: that non-detection of an epitope may not be
equivalent to the absence of a particular molecule. This prob-
lem is highlighted in the present study in which antibodies
specific for different regions of the IgA1 molecule were used to
evaluate tissue from patients with systemic lupus erythemato-
sus (SLE), IgA nephropathy (IgAN), idiopathic membranous
nephropathy (IMN), and anti—glomerular basement membrane
(GBM) nephritis. One of the IgA1 epitopes was "masked" in
subepithelial and linear BM deposits but was detected in
mesangial/subendothelial deposits. This epitope was also hid-
den following binding of IgA1 antinuclear antibodies (ANA) to
nuclear substrates, in vitro. The presence of IgA1 in all loci was
confirmed by reactivity of two other monoclonal anti-IgA1
antibodies.
Methods. Patients with the following diseases were evalu-
ated: SLE, ten patients, IgAN, ten; IMN, two; and anti-GBM
nephritis, one. The diagnosis of SLE was made according to
criteria established by the American Rheumatism Association
[1], and morphologic categories were defined on the basis of
light and electron microscopy as previously described [2]: Two
biopsies demonstrated predominantly mesangial proliferation,
four with membranous nephropathy, and four with diffuse
proliferation. Patients with IgA nephropathy had mesangial
deposits exclusively and no evidence of systemic disease. The
two patients with IMN showed only subepithelial deposits. A
patient with familial nephritis who developed anti-GBM
nephritis in a transplanted kidney manifested by linear deposi-
tion of IgG and IgA along the GBM also was evaluated.
Goat anti-human IgA (a chain specific) (Cappel Laboratories,
Cochranville, Pennsylvania, USA) was used to evaluate IgA in
renal tissue. The IgA localization was confirmed using a mono-
clonal antibody (murine y1K designated 1-29) against whole IgA
as previously described [3, 4]. Those tissues positive for IgA
were evaluated by indirect immunofluorescence for the pres-
ence of IgA1 and IgA2. Three monoclonal antibodies against
IgA1 were used. 1-155-1 (y3X) has been described previously [3,
4]. DLD B4 and DLD A7 (y1K antibodies) were produced by
immunizing Balb/c mice (previously made tolerant to an IgA2
myeloma) with an Fc fragment of an IgA1 myeloma protein. In
a competitive radioimmunoassay DLD B4 and DLD A7 bind all
intact IgA1 myeloma proteins, isolated IgA1 heavy chains, and
Fc fragments of IgA1, but do not bind an IgA1 myeloma that
lacks the CH3 domain (designated WAL) (Delacroix, manu-
script in preparation). These findings indicate that DLD B4 and
DLD A7 are directed against determinants on the CH3 or
carboxyterminal portion of the IgA1 molecule. In contrast,
1-155-1 binds to the CH3 deficient IgA1 myeloma, WAL, but
does not bind to either the Fc or Fab portion of IgA1 myeloma
proteins. These findings suggest that 1-155-1 binds to a carbo-
hydrate antigen found in the hinge region of IgA1. Two mono-
clonal antibodies against IgA2 were used. 14-3-26 (y2BK) has
been described previously [3, 41. The other antibody, DLD D2
(y1K) was produced by immunizing a Balb/c mouse (previously
made tolerant to an IgA1 myeloma protein) with an intact IgA2
myeloma protein. The epitopes recognized by the anti-IgA2
monoclonal antibodies have not been determined because of
resistance of IgA2 to bacterial proteases and the lack of well
characterized CH domain deficient IgA2 myeloma proteins. All
antibodies were used as clonal supernatants. The secondary
antibody was fluorescein isothiocyanate (FITC) conjugated
goat anti-mouse immunoglobulin (FITC-GAMIg) (Cappel Labo-
ratories). Controls were carried out as previously described [5].
In addition, myeloma proteins (courtesy of Dr. Michael Potter,
National Institutes of Health, Bethesda, Maryland, USA) of the
same subclasses as the monoclonal antibodies, were applied to
tissue sections followed by FITC-GAMIg with no reac-
tivity detected. These included: MOPC21-yiK, Y5606-y3X, and
MOPCI41-y2BK.
Kidney biopsy specimens were obtained percutaneously for
clinical indications. The tissue samples were frozen in isopen-
tane prechilled in liquid nitrogen, and 4-nm sections were
prepared for direct and indirect immunofluorescence as previ-
ously described [3, 5].
All kidney sections were evaluated with respect to localiza-
tion, pattern, and distribution as well as intensity graded on the
following scale: 0, no staining; 1+, mild to moderate staining;
and 2+, intense staining. Sections were evaluated indepen-
dently by three observers and observations were uniformly
concordant. The location of immune deposits with relationship
to the GBM was determined by the use of simultaneous
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Table 1. Immunofluorescence staining for IgA1 and IgA2 in glomeruli of patients with SLE, IgAN, IMN, and anti-GBM nephritis
Number of patients with positive immunofluorescence
IgA1 IgA2
Glomerular localization IgAa (1-155-1) (DLD B4, DLD A7)b (14-3
-26) (DLD D2)
SLE (l0)C
Subepithelial 7d 0 7 1 0
Mesangial/Subendothelial 9'I 7 9 1
IgA Nephropathy (10)
Mesangial 10 10 10 0 0
IMN (2)
Subepithelial 0 NDa 0 ND
Anti-GBM Nephritis (1) 1 0 1 0 0
a These figures denote concordant reactivity with a chain specific goat antiserum and a monoclonal antibody to IgA (1—29).
DLD B4 and DLD A7 have concordant reactivity in all tissue sections evaluated.
C The number in parentheses is the total number of patients evaluated with the indicated disease.
d One patient had exclusively subepithelial deposits, three exclusively mesangial subendothelial deposits, and six had deposits in both loci.
Not done.
Fig. 1. MesangialisubendothelialigA deposits in a patient with SLE. A Mesangialisubendothelial deposits detected with goat anti-IgA. (x440) B
Concordant detection of these deposits in a more restricted distribution with a inonoclonal antihod against IgA1 (1-155-1). (x445) C Deposits
detected with monoclonal anti-IgA (1-29) similar to those observed with polyclonal anti-IgA in (A). (x437) D Detection of IgA, with DiD B4. Note
that the immunofluorescence is similar to that observed in (A) and (C) and is not restricted in distribution as in (B). (X426)
immunofluorescence and phase contrast microscopy. These were evaluated in IgA subclass specific ANA assays. Appropri-
observations were confirmed by electron microscopy. ate dilutions of serum were layered over sections of mouse
Ten serum samples from patients with SLE and IgA ANA liver, as a nuclear substrate, in this assay. After 30 mm, the
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Fig. 2. Localization of IgA and IgA, in a patient with SLE with IgA deposits in suhepithelial as well as the mesangial/suhendoihelial locus. A IgA
as detected using polyclonal anti-IgA. Note both subepithelial deposits (arrows) in peripheral capillary loops as well as mesangial deposits (arrows
within the glomerulus). (x883) B IgA1 as detected in the same biopsy specimen with the 1-155-1 antibody. Note that no deposits are detected in
the peripheral loops (arrows). Deposits in the mesangial/subendothelial zones are detected. (x477) C Same sect ion as in (B) photographed under
phase contrast conditions to delineate the peripheral capillary loops (arrows) and GBM. (x477)
tissue sections were washed and hybridoma supernatants were
layered over the tissue for 45 mm followed by washing and
counterstaining with GAMIg-FITC absorbed with human serum
prior to use.
An attempt was made to expose antigenic determinants of
localized IgA by incubation of mouse liver slices with urea (1.0,
3.0, or 5.0 M) for 5, 30, or 60 mm after application of human
sera. Also, three biopsy specimens from patients with SLE as
well as three with IgA nephropathy were incubated in 6 M urea
at 4°C for 30 mm prior to the application of the monoclonal
antibodies.
Results. Glomerular IgA was detected using both polyclonal
and monoclonal (1-29) anti-IgA demonstrating a similar distri-
bution and intensity (Ito 2+) in each often patients with SLE,
two with IMN, ten with IgA nephropathy, and one with
anti-GBM nephritis (Table 1).
Granular IgA deposits were present in a subepithelial locus in
seven patients with SLE (four with membranous nephropathy
and three of four with diffuse proliferation), and in both patients
with IMN. None of these deposits in the lupus tissue were
positive for IgA1 with the 1-155-I antibody but all reacted with
two other monoclonal antibodies specific for IgA1 (DLD B4 and
DLD A7), in an intensity range of ito 2+. IgA2 was detected in
subepithelial deposits of only one patient with SLE using the
14-3-26 antibody. The subepithelial deposits of IgA in the two
patients with IMN failed to react with one antibody to IgA1
(1-155-I) (Table I). Unfortunately, lack of tissue availability
prevented examination with the DLD B4, DLD A7, and DLD
D2 antibodies.
Nine patients with SLE had mesangial/subendothelial depos-
its of igA as did all ten patients with igA nephropathy (Table I).
In seven patients with SLE these were positive for IgA1 in a
restricted distribution using 1-155-I, with Ito 2+ intensity (Fig.
1). In all nine, the deposits reacted with two other monoclonal
antibodies to igA1, DLD B4, and DLD A7, in an intensity and
distribution similar to that seen using alpha chain specific
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Fig. 3. IgA and IgA, localization in a patient with anti-GBM nephritis. A Linear IgA along the GBM as detected by goat anti-IgA. (x570) B No
staining for IgA1 is observed using 1-155-1. (x438) C Concordant with (A), monoclonal anti-IgA (1-29) detects the linear deposits. (X426) D In
contrast to (B), IgA1 is detected in a linear pattern with DLD B4. (x432)
antiserum (Fig. 1). The mesangial deposits in the patients with
IgA nephropathy reacted with all three monoclonal anti-IgA1
antibodies. No IgA2 deposits were detected.
In the six tissue samples from patients with SLE, in which
deposits were present in both subepithelial and mesangi-
al/subendothelial loci, IgA1 was not detected in subepithelial
deposits using the 1-155-1 antibody but was observed using
DLD B4 and DLD A7 (Table 1). However, positive im-
munofluorescence for IgA1 was present in the mesangi-
al/subendothelial zone using all three antibodies (Fig. 2).
In a patient with anti-GBM nephritis whose GBM contained
IgA, 1-155-1 did not detect any deposits whereas DLD B4 and
DLD A7 revealed a linear pattern of IgA1 with an intensity of 1
to 2+ (Fig, 3). IgA2 was not detected (Table 1). No changes in
staining were observed after urea incubation.
Sera from ten patients with SLE were positive for IgA1 ANA
with the DLD B4 and DLD A7 antibodies, but none had
demonstrable reactivity with 1-155-1. IgA2 was not detected
with either monoclonal antibody. Preincubation with urea failed
to uncover IgA1 or lgA2 subclass determinants when stained
with the 1-155-1 antibody or the 14-3-26 antibody against lgA2.
I)iscussion. This study demonstrates that a determinant on
the lgA1 molecule is not detected in subepithelial deposits but is
present in mesangial/subendothelial deposits of patients with
SLE. This determinant also is not seen in anti-GBM nephritis,
IMN, and the in vitro detection of IgA1 ANA.
The inability to detect an antigen in tissue using a monoclonal
antibody does not mean necessarily that the particular molecule
is absent. An alternative explanation as described in this study
is that the epitope on the molecule is hidden or "masked."
Restriction of "masking" to subepithelial sites, the GBM and
the in vitro detection of ANA suggests but does not prove a
unique in situ interaction of antibody and antigen in these loci.
While there is no apriori reason that such "masking" could not
take place in mesangial deposits we did not observe it. The
hidden IgA1 epitope, recognized by one monoclonal antibody
(1-155-1), is within or near the hinge region—a locus that may
be more likely "masked" than determinants on the Fc portion
of the molecule, which are identified by two other monoclonal
antibodies (DLD B4 and DLD A7). Another explanation for
these observations is that the epitope is lost or destroyed,
although this seems unlikely since the same "masking" phe-
nomenon was observed in the binding of IgA1 ANA in vitro.
Despite several possible explanations, the implications for
immunofluorescence microscopy are apparent.
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